Anna Austin, EVP, Corporate Communications (314) 523-8354 Ian Chadsey, Manager, Investor Relations (416) 436-5949 Email: investor.relations@tlcvision.com
TLCVisionReports Record First Quarter
St. Louis, Missouri, May 5, 2005: TLC Vision Corporation (NASDAQ:TLCV; TSX:TLC), North America’s premier eye care services company, today announced its financial results for the three month period ended March 31, 2005. All dollar amounts are expressed in U.S. currency and results are reported in accordance with U.S. generally accepted accounting principles (U.S. GAAP) unless otherwise noted.
To provide maximum transparency in the release for our shareholders, consolidated results excluding the impact of the AMD segment, principally our investment in OccuLogix Inc., will be differentiated usingitalicstext.
First Quarter 2005 Highlights
•
Revenues improved to $71 million, a 9% year-over-year increase
•
Net income increased 19% to $9.6 million oNet income increased 31% (excludes AMD)
•
Earnings per share rose to $0.13 compared to $0.12 per share year-over-year oEPS was $0.16 versus $0.12 per share year over year (excludes AMD)
•
Cash and short-term investments are $142.3 million
•
Cash and short-term investments are $93.3 million, up 11% from the previous quarter (excludes AMD)
Revenues
Total revenues for the first quarter 2005 rose 9% to $71 million compared to $65 million for the same period a year ago. Revenues for the first quarter increased as a result of higher refractive procedure volumes, growing custom mix and continued strong performance from the other healthcare services segment.
Refractive Revenues: Refractive revenues for the first quarter 2005 increased to $55.2 million compared to $50.9 million in 2004, led by 11% revenue growth in the corporate owned centers business.
Other Healthcare Revenues: The company continues to have strong growth from our other healthcare services. Other healthcare revenues were up 11% for the first quarter year-over-year comparisons, and generated 22% of total net revenues. The cataract business continues to drive strong growth, in both mobile and ASC operations.
Earnings
TLCVisionexperienced its 5th consecutive quarter of record, year-over-year earnings which is attributable to higher refractive and cataract procedure volumes and improved gross margins, increasing the leverage in the business model.
First quarter earnings of $9.6 million or $0.13 per share increased 19% from the previous year.
Net income, excluding the AMD segment, was up 31% to $11.2 million versus $8.6 million last year. Earnings per share were $0.16 for the quarter versus $0.12 last year.
Cash
The Company ended the first quarter in a strong financial position. Cash and short-term investments were $142.3 million at the end of the period.
Cash and short-term investments, excluding the AMD segment, totaled $93.3 million, 11% higher than at year-end.
Operating cash flow was $0.08 per share for the first quarter of 2005.
Excluding the AMD segment, operating cash flow was $0.16 per share which was the same as the first quarter last year. Cash generation in the current quarter was impacted by seasonally higher working capital, which should have a positive impact on second quarter cash generation.
“This represents five consecutive quarters of record, year-over-year, earnings for the company,” commented Jim Wachtman, President and Chief Executive Officer. “We continue to deliver impressive earnings growth as a result of higher procedure volumes and a disciplined approach to managing costs. The earnings growth coupled with strong cash flow generation has put us in a very strong financial position to drive our strategic initiatives for the future.”
Other Refractive Operating Metrics
Procedure Volume and Margins:Refractive volumes and gross profit margins increased again this quarter. Total paid laser procedures increased to 58,700. Same store centers refractive volumes increased 9% year-over-year. Surgical procedures continue to favor the centers business, which represent 60% of total refractive volume. Refractive gross profit margins increased to 35% as a result of higher refractive volume and improved custom mix.
CustomLASIK:TLCVisioncontinued to outperform the industry with respect to CustomLASIK adoption. CustomLASIK procedures represented 58% of center volumes, and exited the quarter at 61%.
Conference Call
TLCVisionis pleased to invite all interested parties to participate in a conference call during which these results will be discussed. The call will be held today, May 5, at 10:30 a.m. Eastern Time at 888-694-1321. The call will also be broadcast live and archived on the Company’s web site atwww.tlcv.com under the “Webcasts” link in the Investor Relations section. In addition, the live web cast will be available at various other popular portals and financial web sites.
AboutTLCVision
TLCVisionis North America’s premier eye care services company, providing eye doctors with the tools and technologies needed to deliver high-quality care. We maintain leading positions in Refractive, Cataract and Optometric Services markets, plus the AMD market through our significant ownership in OccuLogix, Inc (NASDAQ: RHEO, TSX: RHE). The key drivers of TLCVision‘s strategy are our affiliated network of over 13,000 eye doctors, proven corporate and consumer marketing and education programs, and access to state of the art clinical technologies. We are supported by strong financial performance, a culture of operational excellence and an experienced management team. The Company’s common shares trade on the NASDAQ National Market under the symbol ‘TLCV’ and on the Toronto Stock Exchange under the symbol ‘TLC’. More information about the Company can be found on the TLCVisionweb site at www.tlcv.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934, which statements can be identified by the use of forward looking terminology, such as “may”, “will”, “expect”, ”intend”, “anticipate”, “estimate”, “predict”, “plans” or “continue” or the negative thereof or other variations thereon or comparable terminology referring to future events or results. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including the timing of expenditures, effects of competition, changes to pricing, acquisitions and expansion opportunities, any of which could cause actual results to vary materially from current results or TLCVision’s anticipated future results. See the Company’s reports filed with the Canadian Securities Regulators and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward looking statements. TLCVision assumes no obligation to update the information contained in this press release.
-30-
TLC VISION CORPORATION CONSOLIDATING STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands except per share amounts)
Three Months Ended March 31, 2005
Three Months Ended March 31, 2004
Results Before
AMD
AMD
Total
Results Before AMD
AMD
Total
Segment
Segment
TLCVision
Segment
Segment
TLCVision
Revenues:
Refractive:
Centers
$
43,291
$
—
$
43,291
$
38,838
$
—
$
38,838
Access
11,880
—
11,880
12,049
—
12,049
Other healthcare services
15,447
431
15,878
14,079
209
14,288
Total revenues
70,618
431
71,049
64,966
209
65,175
Cost of revenues:
Refractive:
Centers
28,099
—
28,099
26,152
—
26,152
Access
7,837
—
7,837
8,172
—
8,172
Other healthcare services
9,635
519
10,154
8,915
223
9,138
Total cost of revenues
45,571
519
46,090
43,239
223
43,462
Gross profit (loss)
25,047
(88
)
24,959
21,727
(14
)
21,713
General and administrative
8,228
3,223
11,451
7,256
97
7,353
Marketing
3,350
185
3,535
2,872
22
2,894
Research and development
--
—
—
—
374
374
Amortization of intangibles
1,011
—
1,011
1,012
—
1,012
Total operating costs
12,589
3,408
15,997
11,140
493
11,633
Operating income (loss)
12,458
(3,496
)
8,962
10,587
(507
)
10,080
Other income
255
—
255
—
—
—
Interest income
716
356
1,072
478
—
478
Interest expense
(457
)
(1
)
(458
)
(881
)
—
(881
)
Minority interests
(2,185
)
1,499
(686
)
(1,874
)
—
(1,874
)
Earnings from equity investments
659
—
659
399
—
399
Income (loss) before income taxes
11,446
(1,642
)
9,804
8,709
(507
)
8,202
Income tax expense
(198
)
—
(198
)
(150
)
—
(150
)
Net income (loss)
$
11,248
$
(1,642
)
$
9,606
$
8,559
$
(507
)
$
8,052
Earnings (loss) per share – diluted
$
0.16
$
(0.03
)
$
0.13
$
0.12
$
0.00
$
0.12
Weighted average number of common shares outstanding – diluted
72,045
72,045
72,045
69,433
69,433
68,433
Note: The AMD segment includes OccuLogix, Inc. (formerly Vascular Sciences Corporation), OccuLogix, L.P. and RHEO Clinic, Inc.
1
TLC VISION CORPORATION CONSOLIDATING BALANCE SHEETS (In thousands)
March 31, 2005 (Unaudited)
December 31, 2004
Results Before
Results Before AMD
AMD
AMD
AMD
Total
Segment
Segment
Total
Segment
Segment
TLCVision
(Unaudited)
(Unaudited)
TLCVision
ASSETS
Current assets
Cash and cash equivalents
$
54,496
$
6,631
$
61,127
$
15,847
$
17,588
$
33,435
Short-term investments
38,850
42,278
81,128
68,515
42,500
111,015
Accounts receivable
19,806
657
20,463
16,489
954
17,443
Prepaids and other current assets
12,557
3,511
16,068
12,212
1,609
13,821
Total current assets
125,709
53,077
178,786
113,063
62,651
175,714
Intercompany
1,955
(1,955
)
—
1,877
(1,877
)
—
Restricted cash
909
—
909
932
—
932
Investments and other assets
10,629
5,383
16,012
10,482
—
10,482
Goodwill
52,751
—
52,751
53,774
—
53,774
Intangibles, net
17,026
103
17,129
18,037
103
18,140
Fixed assets, net
45,060
563
45,623
45,636
563
46,199
Total assets
$
254,039
$
57,171
$
311,210
$
243,801
$
61,440
$
305,241
LIABILITIES
Accounts payable
$
10,494
$
560
$
11,054
$
8,491
$
225
$
8,716
Accrued liabilities
20,995
2,514
23,509
23,425
3,714
27,139
Current portion of long-term debt
6,327
—
6,327
8,664
—
8,664
Total current liabilities
37,816
3,074
40,890
40,580
3,939
44,519
Long-term debt, less current maturities
9,654
—
9,654
9,991
—
9,991
Other long-term liabilities
3,166
—
3,166
2,242
480
2,722
Minority interests
9,397
26,522
35,919
9,307
27,915
37,222
SHAREHOLDERS’ EQUITY
Capital stock
430,731
30,193
460,924
428,877
30,082
458,959
Option and warranty equity
2,095
—
2,095
2,872
—
2,872
Accumulated deficit
(238,820
)
(2,618
)
(241,438
)
(250,068
)
(976
)
(251,044
)
Total shareholders’ equity
194,006
27,575
221,581
181,681
29,106
210,787
Total liabilities and shareholders’ equity
$
254,039
$
57,171
$
311,210
$
243,801
$
61,440
$
305,241
Note: The AMD segment includes OccuLogix, Inc. (formerly Vascular Sciences Corporation), OccuLogix, L.P. and RHEO Clinic, Inc.
2
TLC VISION CORPORATION CONSOLIDATING STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands except per share amounts)
Three Months Ended March 31, 2005
Three Months Ended March 31, 2004
Results Before
AMD
AMD
Total
Results Before AMD
AMD
Total
Segment
Segment
TLCVision
Segment
Segment
TLCVision
OPERATING ACTIVITIES
Net Income (loss)
$
11,248
$
(1,642
)
$
9,606
$
8,559
$
(507
)
$
8,052
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization
3,971
46
4,017
4,546
11
4,557
Write-off of investment in research and development arrangement
—
—
—
—
374
374
Minority interests
2,185
(1,499
)
686
1,874
—
1,874
Earnings from equity investments
(659
)
—
(659
)
(399
)
—
(399
)
Loss (gain) on disposal of fixed assets
(96
)
—
(96
)
730
—
730
Gain on sale of subsidiaries
(319
)
—
(319
)
(1,278
)
—
(1,278
)
Compensation expense
69
—
69
420
—
420
Changes in operating assets and liabilities, net of acquisitions and dispositions
(4,627
)
(2,872
)
(7,499
)
(3,576
)
107
(3,469
)
Cash from operating activities
11,772
(5,967
)
5,805
10,876
(15
)
10,861
INVESTING ACTIVITIES
Purchases of fixed assets
(2,681
)
(46
)
(2,727
)
(1,570
)
—
(1,570
)
Proceeds from sale of fixed assets
454
—
454
147
—
147
Proceeds from divestitures of investments and subsidiaries, net
3,430
—
3,430
(271
)
—
(271
)
Distributions and loan payments received from equity investments
556
—
556
—
—
—
Investment in research and development arrangements
—
—
—
(374
)
—
(374
)
Acquisitions and investments
(443
)
—
(443
)
(4,210
)
—
(4,210
)
Proceeds from sale of short-term investments
34,350
4,400
38,750
—
—
—
Purchases of short-term investments
(4,685
)
(4,178
)
(8,863
)
(7,125
)
—
(7,125
)
Purchases of long-term investments
—
(5,383
)
(5,383
)
—
—
—
Other
(125
)
—
(125
)
544
—
544
Cash from investing activities
30,856
(5,207
)
25,649
(12,859
)
—
(12,859
)
FINANCING ACTIVITIES
Restricted cash movement
23
—
23
7
—
7
Principal payments of debt financing and capital leases
(4,219
)
—
(4,219
)
(4,566
)
—
(4,566
)
Proceeds from debt financing
1,117
—
1,117
—
—
—
Distributions to minority interests
(1,977
)
—
(1,977
)
(1,355
)
—
(1,355
)
Proceeds from issuance of common stock
1,077
—
1,077
8,287
—
8,287
Proceeds from issuance of OccuLogix, Inc. common stock
—
217
217
—
—
—
Cash from financing activities
(3,979
)
217
(3,762
)
2,373
—
2,373
Net increase (decrease) in cash and cash equivalents during the period
38,649
(10,957
)
27,692
390
(15
)
375
Cash and cash equivalents, beginning of period
15,847
17,588
33,435
21,554
26
21,580
Cash and cash equivalents, end of period
$
54,496
$
6,631
$
61,127
$
21,944
$
11
$
21,955
Operating cash flow per diluted share
$
0.16
$
(0.08
)
$
0.08
$
0.16
$
(0.00
)
$
0.16
Note: The AMD segment includes OccuLogix, Inc. (formerly Vascular Sciences Corporation), OccuLogix, L.P. and RHEO Clinic, Inc.
3
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.
